Biomea Fusion posts icovamenib presentation detailing Phase 2 type 1 diabetes data

• Biomea Fusion highlighted Phase 2 COVALENT-112 data for menin inhibitor icovamenib in stage 3 type 1 diabetes.
• Cohort 1 patients diagnosed within 3 years showed a 52% mean increase in mixed-meal C-peptide AUC at week 12 on 200 mg daily dosing (p<0.001; n=5).
• Follow-up through week 52 showed C-peptide AUC was largely preserved in Cohort 1 at 200 mg, with a 7.1% decline from baseline (n=4).
• Dose-response favored 200 mg over 100 mg, with stronger activity in earlier-diagnosis patients versus those 3-15 years from diagnosis.
• Biomea Fusion outlined a proposed next Phase 2 study in adults diagnosed within 3 years, featuring a 6-month primary C-peptide AUC endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.